RESEARCH TRIANGLE PARK – The global marketplace for a robotic surgical system developed by Triangle-based TransEnterix continues to expand.
The company announced Monday that the Senhance Surgical System has been approved for use in Japan. US and EU regulators have already approved Senhance. The Japan approval sent TransEnterix (TRXC) shares up more than 10 percent in early trading.
The decision is seen by TransEnterix CEO Todd Pope as a “pivotal milestone” for the company since “Japan is second only to the U.S. as the world’s largest surgical robotics market.”